Rapid Microbiology Testing Kits Market Size, Key Drivers, Growth, Demand, and Analysis 2024-2033

The Rapid Microbiology Testing Kits Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Rapid Microbiology Testing Kits Market:

https://www.thebusinessresearchcompany.com/report/rapid-microbiology-testing-kits-global-market-report

According to The Business Research Company’s Rapid Microbiology Testing Kits Global Market Report 2024, The rapid microbiology testing kits market size has grown steadily in recent years. It will grow from $4.61 billion in 2023 to $4.82 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, increasing awareness of the benefits of rapid microbiology testing, food safety concerns, growing pharmaceutical manufacturing.

The rapid microbiology testing kits market size is expected to see steadily grown in the next few years. It will grow to $6.35 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to public health emergencies, foodborne pathogen detection, environmental monitoring, biopharmaceutical growth. Major trends in the forecast period include advances in rapid microbiology testing technology, customization and data integration, nanotechnology and microfluidics, point-of-care testing, digital microbiology, antimicrobial susceptibility testing.

The rising number of infectious diseases is one of the major drivers for the rapid microbiology testing kits market. Rapid diagnostic tests are faster, more reliable, and more widely available than traditional tests. As the number of infectious disease cases increases, the need for tests to confirm these diseases also increases. With the increasing demand for microbiology tests, the need for rapid microbiology tests is increasing as it gives quicker results than normal microbiology tests. For example, according to the Centers for Disease Control and Prevention (CDC) Trusted Source, the number of visits to physician offices with infectious and parasitic diseases as the primary diagnosis was 15.5 million and the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis was 3.7 million per year.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=2541&type=smp

The rapid microbiology testing kits market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Kits, Consumables

2) By Testing Type: Growth-Based Rapid Microbiology Testing Kits, Cellular Component-Based Rapid Microbiology Testing Kits, Nucleic Acid-Based Rapid Microbiology Testing Kits, Viability-Based Rapid Microbiology Testing Kits, Other Rapid Microbiology Testing Kits Methods

3) By Application: Clinical Disease Diagnosis, Food And Beverage Testing, Pharmaceutical And Biological Drug Testing, Cosmetics And Personal Care Products Testing, Environmental Testing, Research Applications, Other Applications

Major companies operating in the remdesivir market are receiving FDA approvals for new drugs such as Veklury (Remdesivir) to increase their profitability in the market. Veklury (remdesivir) is an antiviral medication used to treat COVID-19 in adults and pediatric patients who are at least 28 days old and weigh at least 3 kg. For instance, in January 2022, Gilead Sciences Inc., a US-based pharmaceuticals company announced that Food and Drug Administration has approved its new drug called Veklury (Remdesivir). Veklury is used to treat mild to moderate COVID-19 symptoms in adults and children who are hospitalized or not and are at high risk for developing severe COVID-19, including hospitalization or death.

The rapid microbiology testing kits market report table of contents includes: